FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes

Ujas Parikh; Charles Marcus; Rutuparna Sarangi; Mehdi Taghipour; Rathan M Subramaniam

doi:10.1016/j.cpet.2015.03.001

FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes

PET Clin. 2015 Jul;10(3):327-43. doi: 10.1016/j.cpet.2015.03.001. Epub 2015 Apr 16.

Authors

Ujas Parikh¹, Charles Marcus¹, Rutuparna Sarangi¹, Mehdi Taghipour¹, Rathan M Subramaniam²

Affiliations

¹ Russell H Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, JHOC 3230, 601 North Caroline Street, Baltimore, MD 21287, USA.
² Russell H Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, JHOC 3230, 601 North Caroline Street, Baltimore, MD 21287, USA; Department of Oncology, Johns Hopkins School of Medicine, 401 North Broadway, Baltimore, MD 21231, USA; Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, 624 North Broadway, Baltimore, MD 21205, USA. Electronic address: rsubram4@jhmi.edu.

PMID: 26099670
DOI: 10.1016/j.cpet.2015.03.001

Abstract

Fludeoxyglucose F 18 ((18)F-FDG) PET/CT has not been shown to offer additional benefit in the initial diagnosis of pancreatic cancer, but studies show benefit of (18)F-FDG PET/CT in initial staging and patient prognosis. There is evidence for (18)F-FDG PET and (18)F-FDG PET/CT in staging and prognosis of cholangiocarcinoma and gallbladder cancer. (18)F-FDG PET/CT has shown promise in staging liver malignancies by detecting extrahepatic metastasis. There is evidence supporting the ability of PET/CT in predicting prognosis in patients with hepatocellular carcinoma. Evidence is evolving for the role of (18)F-FDGPET/CT in predicting prognosis and survival in patients with colorectal liver metastasis.

Keywords: (18)F-FDG PET/CT; Hepatocellular carcinoma; Pancreatic cancer.

Publication types

Review

MeSH terms

Bile Duct Neoplasms / diagnostic imaging*
Bile Duct Neoplasms / pathology
Cholangiocarcinoma / diagnostic imaging*
Cholangiocarcinoma / pathology
Female
Fluorodeoxyglucose F18
Gallbladder Neoplasms / diagnostic imaging*
Gallbladder Neoplasms / pathology
Humans
Liver Neoplasms / diagnostic imaging*
Liver Neoplasms / pathology
Male
Multimodal Imaging / methods
Neoplasm Staging
Pancreatic Neoplasms / diagnostic imaging*
Pancreatic Neoplasms / pathology
Positron-Emission Tomography / methods
Prognosis
Radiopharmaceuticals
Tomography, X-Ray Computed / methods
Treatment Outcome

Substances

Radiopharmaceuticals
Fluorodeoxyglucose F18